PCSK9抑制剂与依折麦布降低心血管事件:按风险分层的临床实践指南
该BMJ临床实践指南由国际专家组按GRADE方法制定,针对已用最大剂量他汀或他汀不耐受且LDL-C>1.8 mmol/L(>70 mg/dL)的成人,按低、中、高、极高四层心血管风险给出分层推荐。多数推荐为弱推荐,强调共同决策;低风险人群强烈推荐不加第二种降脂药。选择加药时建议优先依折麦布而非PCSK9抑制剂。证据来自14项试验、83 660例参与者的系统评价与网络Meta分析:PCSK9抑制剂或依折麦布可能减少极高/高风险患者心肌梗死和卒中,对死亡率无影响,中/低风险无获益;PCSK9抑制剂注射部位反应5年每1000人多15例。
要点
- 已用最大剂量他汀的极高/高风险成人,指南建议(弱推荐)加第二种降脂药;低风险者强烈推荐不加。
- 他汀不耐受的极高/高风险成人,指南推荐使用降脂药;低风险者强烈推荐不加。
- 需加第二种降脂药时,指南建议(弱推荐)优先选依折麦布而非PCSK9抑制剂。
- 已用他汀的极高风险成人及他汀不耐受的极高/高风险成人,指南建议(弱推荐)在依折麦布基础上再加PCSK9抑制剂。
- 应用推荐前须先判定患者心血管风险分层,可选用基于已知危险因素组合的可靠风险计算器。
适用人群与场景
- 成人,LDL-C>1.8 mmol/L(>70 mg/dL),且已服用最大剂量他汀或对他汀不耐受。
- 按心血管风险分为低、中、高、极高四组,推荐因风险组而异。
诊断标准与关键阈值
- 需先识别患者所属心血管风险组(低、中、高、极高),才能应用本指南推荐。
- 建议针对不同地理区域,使用基于已知危险因素组合的可靠风险计算器估计心血管风险。
处置流程与药物剂量
- 已用他汀者:极高和高风险建议(弱推荐)加第二种降脂药;低风险推荐不加。
- 他汀不耐受者:极高和高风险推荐使用降脂药;低风险推荐不加。
- 选择加第二种降脂药时,建议(弱推荐)优先选依折麦布而非PCSK9抑制剂。
- 已用他汀的极高风险成人,以及他汀不耐受的极高和高风险成人,建议(弱推荐)在依折麦布基础上再加PCSK9抑制剂。
- 多数推荐为弱推荐,应用时依赖共同决策;可借助交互式证据摘要和决策辅助工具。
研究设计与关键结果
- 关联的系统评价与网络Meta分析纳入14项试验、83 660例参与者:PCSK9抑制剂或依折麦布可能减少极高和高风险患者的心肌梗死和卒中,对死亡率无影响(中至高确定性证据),对中、低风险者无获益。
- PCSK9抑制剂与依折麦布在减少非致死性心肌梗死或卒中方面可能效果相似(低确定性证据)。
- 相对获益一致,但绝对获益随个体心血管风险变化:例如每1000人加用PCSK9抑制剂的5年获益,从最低风险的减少2例卒中到最高风险的减少21例。
- 两项关于危害的系统评价发现这些药物无重要不良事件(中至高确定性证据);PCSK9抑制剂需注射,有时出现注射部位反应,5年每1000人多15例。
证据类型、等级与局限
- 证据类型:临床实践指南,采用GRADE方法,由包括患者、临床医生和方法学家的国际专家组制定。
- 关联的系统评价与网络Meta分析(14项试验,83 660例参与者)提供获益证据;两项系统评价提供危害证据。
- 关键不确定性:大多数人所认为重要的心血管风险降低与负担和危害之间的权衡仍不清楚。
- 推荐多为弱推荐,反映小组认为卒中与心肌梗死的小幅减少与负担和有限危害之间接近平衡。
对床旁实践的改变
- 对已用最大剂量他汀或他汀不耐受、LDL-C>1.8 mmol/L的成人,先判定心血管风险分层再决定是否加药。
- 极高和高风险者可考虑加用依折麦布或PCSK9抑制剂;低风险者不加第二种降脂药。
- 需加药时优先考虑依折麦布而非PCSK9抑制剂;极高风险及他汀不耐受的极高/高风险者可在依折麦布基础上加PCSK9抑制剂。
- 多数推荐为弱推荐,作者强调与患者共同决策,并考虑药物的可及性和费用。
指南或共识出处
- BMJ临床实践指南:PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations(BMJ)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CLINICAL QUESTION: In adults with low density lipoprotein (LDL) cholesterol levels >1.8 mmol/L (>70 mg/dL) who are already taking the maximum dose of statins or are intolerant to statins, should another lipid-lowering drug be added, either a proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor or ezetimibe, to reduce the risk of major cardiovascular events? If so, which drug is preferred? Having decided to use one, should we add the other lipid-lowering drug?
CURRENT PRACTICE: Most guidelines emphasise LDL cholesterol targets in their recommendations for prescribing PCSK9 inhibitors and/or ezetimibe in adults at high risk of experiencing a major adverse cardiovascular event. However, to achieve these goals in very high risk patients with statins alone is almost impossible, so physicians are increasingly considering other lipid-lowering drugs solely for achieving LDL cholesterol treatment goals rather than for achieving important absolute cardiovascular risk reduction. Most guidelines do not systematically assess the cardiovascular benefits of adding PCSK9 inhibitors and/or ezetimibe for all risk groups across primary and secondary prevention, nor do they report, in accordance with explicit judgments of assumed patients' values and preferences, absolute benefits and harms and potential treatment burdens.
RECOMMENDATIONS: The guideline panel provided mostly weak recommendations, which means we rely on shared decision making when applying these recommendations. For adults already using statins, the panel suggests adding a second lipid-lowering drug in people at very high and high cardiovascular risk but recommends against adding it in people at low cardiovascular risk. For adults who are intolerant to statins, the panel recommends using a lipid-lowering drug in people at very high and high cardiovascular risk but against adding it in those at low cardiovascular risk. When choosing to add another lipid-lowering drug, the panel suggests ezetimibe in preference to PCSK9 inhibitors. The panel suggests further adding a PCSK9 inhibitor to ezetimibe for adults already taking statins at very high risk and those at very high and high risk who are intolerant to statins.
HOW THIS GUIDELINE WAS CREATED: An international panel including patients, clinicians, and methodologists produced these recommendations following standards for trustworthy guidelines and using the GRADE approach. The panel identified four risk groups of patients (low, moderate, high, and very high cardiovascular risk) and primarily applied an individual patient perspective in moving from evidence to recommendations, though societal issues were a secondary consideration. The panel considered the balance of benefits and harms and burdens of starting a PCSK9 inhibitor and/or ezetimibe, making assumptions of adults' average values and preferences. Interactive evidence summaries and decision aids accompany multi-layered recommendations, developed in an online authoring and publication platform (www.magicapp.org) that also allows re-use and adaptation.
THE EVIDENCE: A linked systematic review and network meta-analysis (14 trials including 83 660 participants) of benefits found that PCSK9 inhibitors or ezetimibe probably reduce myocardial infarctions and stroke in patients with very high and high cardiovascular risk, with no impact on mortality (moderate to high certainty evidence), but not in those with moderate and low cardiovascular risk. PCSK9 inhibitors may have similar effects to ezetimibe on reducing non-fatal myocardial infarction or stroke (low certainty evidence). These relative benefits were consistent, but their absolute magnitude varied based on cardiovascular risk in individual patients (for example, for 1000 people treated with PCSK9 inhibitors in addition to statins over five years, benefits ranged from 2 fewer strokes in the lowest risk to 21 fewer in the highest risk). Two systematic reviews on harms found no important adverse events for these drugs (moderate to high certainty evidence). PCSK9 inhibitors require injections that sometimes result in injection site reactions (best estimate 15 more per 1000 in a 5 year timeframe), representing a burden and harm that may matter to patients. The MATCH-IT decision support tool allows you to interact with the evidence and your patients across the alternative options: https://magicevidence.org/match-it/220504dist-lipid-lowering-drugs/.
UNDERSTANDING THE RECOMMENDATIONS: The stratification into four cardiovascular risk groups means that, to use the recommendations, physicians need to identify their patient's risk first. We therefore suggest, specific to various geographical regions, using some reliable risk calculators that estimate patients' cardiovascular risk based on a mix of known risk factors. The largely weak recommendations concerning the addition of ezetimibe or PCSK9 inhibitors reflect what the panel considered to be a close balance between small reductions in stroke and myocardial infarctions weighed against the burdens and limited harms.Because of the anticipated large variability of patients' values and preferences, well informed choices warrant shared decision making. Interactive evidence summaries and decision aids linked to the recommendations can facilitate such shared decisions. The strong recommendations against adding another drug in people at low cardiovascular risk reflect what the panel considered to be a burden without important benefits. The strong recommendation for adding either ezetimibe or PCSK9 inhibitors in people at high and very high cardiovascular risk reflect a clear benefit.The panel recognised the key uncertainty in the evidence concerning patient values and preferences, namely that what most people consider important reductions in cardiovascular risks, weighed against burdens and harms, remains unclear. Finally, availability and costs will influence decisions when healthcare systems, clinicians, or people consider adding ezetimibe or PCSK9 inhibitors.
参考来源
- Hao Q, Aertgeerts B, Guyatt G, et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. BMJ. 2022. PMID: 35508320. doi:10.1136/bmj-2021-069066
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。